ArticleThe oncologist2025
Prognostic index for predicting outcomes of trastuzumab deruxtecan in HER2 expressing metastatic breast cancer: a real-world multicenter study.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Trastuzumab Deruxtecan-Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer: Real-World Outcomes and Treatment Transition Patterns in a Chinese Cohort.Current oncology (Toronto, Ont.) · 2026Article
- Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan.BMC cancer · 2026Article
- Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer.Therapeutic advances in medical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTrastuzumab deruxtecan (T-DXd) has shown efficacy in human epidermal growth factor receptor 2 (HER2)-positive and HER2-low metastatic breast cancer (MBC), but real-world prognostic data in heavily pre-treated patients are limited. This study evaluates T-DXd's real-world efficacy and identifies predictive factors.
methodsOur study included 317 patients (HER2-positive: n = 173; HER2-low: n = 144) treated with T-DXd between January 3, 2020, and September 9, 2024. Outcomes included real-world progression-free survival (rwPFS), overall survival (rwOS), objective response rate (ORR), and safety. A prognostic index was developed using clinical parameters.
resultsIn the HER2-positive cohort, ORR was 44.5%, with a median rwPFS of 10.5 months and rwOS of 29.9 months. Early-line T-DXd use (first or second line) improved rwPFS and rwOS compared with later lines (P < .0001), while prior tubulin-inhibitor antibody-drug conjugates (ADCs) were associated with inferior outcomes. In the HER2-low cohort, ORR was 24.3%, with a median rwPFS of 5.6 months, and rwOS of 18.5 months. Prior exposure to topoisomerase-inhibitor-payload ADCs significantly reduced rwPFS (1.97 vs. 5.97 months, P < .0001) and rwOS (5.77 vs. 18.9 months, P < .0001). Primary resistance rates were higher in HER2-low disease (24.3% vs. 12.7%, P = .011). Prognostic index incorporating treatment lines, HER2 expression, and prior ADC exposure effectively stratified patients into risk groups with distinct survival outcomes.
conclusionsT-DXd shows clinical benefit in HER2-expressing MBC, with efficacy influenced by treatment line, HER2 expression, and prior ADC payload type. The prognostic index could aid in personalizing therapy, optimizing patient selection for T-DXd in real-world practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.